BRIEF—TILT Biotherapeutics closes of 22 million-euro financing

Finland-based clinical-stage biotech TILT Biotherapeutics has announced the final close of its 22 million-euro ($23.8 million) round.

This follows on from the first close of 10 million eros in June 2022.

The financing was led by Finland’s Lifeline Ventures, an early-stage venture capital firm founded by serial entrepreneurs.

The funding will be used to advance to Phase II the company’s combination trials which use oncolytic immunotherapies synergistically with checkpoint inhibitors.

TILT Biotherapeutics’ founder and chief executive Akseli Hemminki said: “We’re pleased to have achieved this round of 22 million euros to advance our promising pipeline of armed oncolytic viruses. Our trials are progressing well through Phase I, and this new funding will support us in progressing them into Phase II, another key step for these new therapies to reach patients in a range of cancers.”